HCV Interview with Sanjeev Arora, MD, Project ECHO Founder

Merck has launched phase 3 trials for MK-8527, a promising once-monthly HIV prevention pill, aiming to enhance PrEP options globally.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.

As authorities record data on the largest US measles outbreak in decades, 79% of Americans support school vaccine mandates for children, an encouraging result.